Zhejiang Hisun Pharmaceutical's (SHA:600267) cytarabine for injection obtained a drug registration certificate from China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.
The certificate for the marketing of the acute non-lymphocytic leukemia drug is valid until June 17, 2029, the Thursday disclosure added.
Shares of the company dropped more than 2% in recent trade.
Price (RMB): ¥7.06, Change: ¥-0.15, Percent Change: -2.08%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments